2026mag
MRNA May 2026 · Hold
Moderna is undergoing a high-risk transition. Following the collapse of its COVID-19 vaccine revenues, it is absorbing multi-billion dollar operating losses as it sustains a massive $3.1B R&D engine. The base case assumes its validated mRNA platform produces sufficient new blockbusters (RSV, CMV, personalized oncology) to return to revenue growth and reach steady-state profitability by the end of the decade.Latest published research · analyzed 2026-05-13 · historical · sources unverified